Key facts
- It has raised $21.7M; the latest was Later Stage VC in Jan 2025.
- Notable investors include Korea Investment Partners, Korea Development Bank, Schmidt (South Korea), DAYLI Partners, A Ventures — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Nextgen Bioscience
- ·The full record, as it builds
Funding rounds
No funding rounds for Nextgen Bioscience are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Nextgen Bioscience
Developer of a therapeutic drug designed for the treatment of fibrosis by conducting clinical trials. The company's platform includes candidate substances for three diseases, such as wet macular degeneration, non-alcoholic steatohepatitis, and pulmonary fibrosis, and also provides treatment for ocular fibrosis disease, enabling patients suffering from refractory fibrosis to get treatment for fibrosis disease, which has a medically underserved demand due to a lack of treatment.
- Sector
- Healthcare
- HQ
- Seongnam, South Korea
- Founded
- 2018
- Employees
- 15
- Website
- nextgenbio.co.kr/
- Ownership
- Privately Held (backing)
Nextgen Bioscience doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nextgen Bioscience shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nextgen Bioscience in its N-PORT filings yet. We sweep new filings monthly.